Insulin therapy in type 2 diabetes.
暂无分享,去创建一个
[1] Philippe Lehert,et al. Combination of insulin and metformin in the treatment of type 2 diabetes. , 2002, Diabetes care.
[2] J. Buse,et al. Amylin Replacement With Pramlintide in Type 1 and Type 2 Diabetes: A Physiological Approach to Overcome Barriers With Insulin Therapy , 2002 .
[3] P. Cryer,et al. Hypoglycaemia: The limiting factor in the glycaemic management of Type I and Type II Diabetes* , 2002, Diabetologia.
[4] J. Leahy. Intensive Insulin Therapy in Type 1 Diabetes Mellitus , 2002 .
[5] M Peyrot,et al. Psychological issues and treatments for people with diabetes. , 2001, Journal of clinical psychology.
[6] J. Rosenstock,et al. Basal insulin therapy in type 2 diabetes: 28-week comparison of insulin glargine (HOE 901) and NPH insulin. , 2001, Diabetes care.
[7] D. Nathan. Inhaled Insulin for Type 2 Diabetes: Solution or Distraction? , 2001, Annals of Internal Medicine.
[8] W. Cefalu,et al. Inhaled Human Insulin Treatment in Patients with Type 2 Diabetes Mellitus , 2001, Annals of Internal Medicine.
[9] K. Hermansen,et al. Comparison of the soluble basal insulin analog insulin detemir with NPH insulin: a randomized open crossover trial in type 1 diabetic subjects on basal-bolus therapy. , 2001, Diabetes care.
[10] S. Mudaliar,et al. New oral therapies for type 2 diabetes mellitus: The glitazones or insulin sensitizers. , 2001, Annual review of medicine.
[11] G. Eisenbarth,et al. MICA polymorphism is associated with type 1 diabetes in the Korean population. , 2001, Diabetes care.
[12] P. Brunetti,et al. Pharmacokinetics and pharmacodynamics of subcutaneous injection of long-acting human insulin analog glargine, NPH insulin, and ultralente human insulin and continuous subcutaneous infusion of insulin lispro. , 2000, Diabetes.
[13] D. Laight. Therapeutic approaches to insulin resistance , 2000 .
[14] A. Lindholm,et al. Insulin aspart vs. human insulin in the management of long‐term blood glucose control in Type 1 diabetes mellitus: a randomized controlled trial , 2000, Diabetic medicine : a journal of the British Diabetic Association.
[15] P. Raskin,et al. A 16-week comparison of the novel insulin analog insulin glargine (HOE 901) and NPH human insulin used with insulin lispro in patients with type 1 diabetes. , 2000, Diabetes care.
[16] S. Schwartz,et al. Therapy focused on lowering postprandial glucose, not fasting glucose, may be superior for lowering HbA1c. IOEZ Study Group. , 2000, Diabetes care.
[17] J. Rosenstock,et al. Basal insulin glargine (HOE 901) versus NPH insulin in patients with type 1 diabetes on multiple daily insulin regimens. U.S. Insulin Glargine (HOE 901) Type 1 Diabetes Investigator Group. , 2000, Diabetes care.
[18] A. Riis,et al. Pharmacokinetics and pharmacodynamics of a premixed formulation of soluble and protamine-retarded insulin aspart , 2000, European Journal of Clinical Pharmacology.
[19] H. Yki-Järvinen,et al. Less nocturnal hypoglycemia and better post-dinner glucose control with bedtime insulin glargine compared with bedtime NPH insulin during insulin combination therapy in type 2 diabetes. HOE 901/3002 Study Group. , 2000, Diabetes care.
[20] A. Zinsmeister,et al. Pramlintide, an amylin analog, selectively delays gastric emptying: potential role of vagal inhibition. , 2000, American journal of physiology. Gastrointestinal and liver physiology.
[21] M. Johannesson,et al. Cost-effectiveness of intense insulin treatment after acute myocardial infarction in patients with diabetes mellitus; results from the DIGAMI study. , 2000, European heart journal.
[22] L Heinemann,et al. Time-action profile of the long-acting insulin analog insulin glargine (HOE901) in comparison with those of NPH insulin and placebo. , 2000, Diabetes care.
[23] I. Hirsch,et al. Less hypoglycemia with insulin glargine in intensive insulin therapy for type 1 diabetes. U.S. Study Group of Insulin Glargine in Type 1 Diabetes. , 2000, Diabetes care.
[24] M. Shichiri,et al. Long-term results of the Kumamoto Study on optimal diabetes control in type 2 diabetic patients. , 2000, Diabetes care.
[25] T. Pieber,et al. Efficacy and safety of HOE 901 versus NPH insulin in patients with type 1 diabetes. The European Study Group of HOE 901 in type 1 diabetes. , 2000, Diabetes care.
[26] B. Campaigne,et al. Improved postprandial glycemic control with Humalog Mix75/25 after a standard test meal in patients with type 2 diabetes mellitus. , 2000, Clinical therapeutics.
[27] S. Bonner-Weir,et al. Exendin-4 stimulates both beta-cell replication and neogenesis, resulting in increased beta-cell mass and improved glucose tolerance in diabetic rats. , 1999, Diabetes.
[28] J. Olefsky,et al. A comparison of troglitazone and metformin on insulin requirements in euglycemic intensively insulin-treated type 2 diabetic patients. , 1999, Diabetes.
[29] C. Bogardus,et al. The natural history of insulin secretory dysfunction and insulin resistance in the pathogenesis of type 2 diabetes mellitus. , 1999, The Journal of clinical investigation.
[30] P. Raskin,et al. Effects of Metformin in Patients with Poorly Controlled, Insulin-Treated Type 2 Diabetes Mellitus , 1999, Annals of Internal Medicine.
[31] P. Roach,et al. Improved postprandial glycemic control during treatment with Humalog Mix25, a novel protamine-based insulin lispro formulation. Humalog Mix25 Study Group. , 1999, Diabetes care.
[32] R. Holman,et al. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group. , 1999, JAMA.
[33] L. Ryysy,et al. Comparison of Bedtime Insulin Regimens in Patients with Type 2 Diabetes Mellitus , 1999, Annals of Internal Medicine.
[34] Melvin Prince,et al. The Diabetes Prevention Program. Design and methods for a clinical trial in the prevention of type 2 diabetes. , 1999, Diabetes care.
[35] D. Bruttomesso,et al. Restoration of early rise in plasma insulin levels improves the glucose tolerance of type 2 diabetic patients. , 1999, Diabetes.
[36] F. Nuttall,et al. Effect of intensive glycemic control on fibrinogen, lipids, and lipoproteins: Veterans Affairs Cooperative Study in Type II Diabetes Mellitus. , 1998, Archives of internal medicine.
[37] R. Holman,et al. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. , 1998 .
[38] R. Holman,et al. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34) , 1998, The Lancet.
[39] J. Buse,et al. Troglitazone Use in Insulin-Treated Type 2 Diabetic Patients , 1998, Diabetes Care.
[40] M. Riddle,et al. Beginning Insulin Treatment of Obese Patients With Evening 70/30 Insulin Plus Glimepiride Versus Insulin Alone , 1998, Diabetes Care.
[41] O. Kolterman,et al. Pramlintide, a Synthetic Analog of Human Amylin, Improves the Metabolic Profile of Patients With Type 2 Diabetes Using Insulin , 1998, Diabetes Care.
[42] F. Nuttall,et al. Response to Intensive Therapy Steps and to Glipizide Dose in Combination With Insulin in Type 2 Diabetes: VA feasibility study on glycemic control and complications (VA CSDM) , 1998, Diabetes Care.
[43] K. Flegal,et al. Prevalence of Diabetes, Impaired Fasting Glucose, and Impaired Glucose Tolerance in U.S. Adults: The Third National Health and Nutrition Examination Survey, 1988–1994 , 1998, Diabetes Care.
[44] P. Raskin,et al. Effect of troglitazone in insulin-treated patients with type II diabetes mellitus. Troglitazone and Exogenous Insulin Study Group. , 1998, The New England journal of medicine.
[45] L. Niskanen,et al. Effect of obesity on the response to insulin therapy in noninsulin-dependent diabetes mellitus. , 1997, Journal of Clinical Endocrinology and Metabolism.
[46] F. Holleman,et al. Reduced Frequency of Severe Hypoglycemia and Coma in Well-Controlled IDDM Patients Treated With Insulin Lispro , 1997, Diabetes Care.
[47] W. Manning,et al. Starting insulin therapy in patients with type 2 diabetes: effectiveness, complications, and resource utilization. , 1997, JAMA.
[48] J. Colwell. Controlling type 2 diabetes: are the benefits worth the costs? , 1997, JAMA.
[49] L. Vignati,et al. Mealtime treatment with insulin analog improves postprandial hyperglycemia and hypoglycemia in patients with non-insulin-dependent diabetes mellitus. Multicenter Insulin Lispro Study Group. , 1997, Archives of internal medicine.
[50] K. Malmberg. Prospective randomised study of intensive insulin treatment on long term survival after acute myocardial infarction in patients with diabetes mellitus , 1997, BMJ.
[51] F. Nuttall,et al. Cardiovascular events and correlates in the Veterans Affairs Diabetes Feasibility Trial. Veterans Affairs Cooperative Study on Glycemic Control and Complications in Type II Diabetes. , 1997, Archives of internal medicine.
[52] R. Henry,et al. Diagnosis and Management of Type 2 Diabetes , 1997 .
[53] R. Klein,et al. Evaluations of Retinopathy in the VA Cooperative Study on Glycemic Control and Complications in Type II Diabetes (VA CSDM): A feasibility study , 1996, Diabetes Care.
[54] R. Henry,et al. Acute Effects of Intraperitoneal Versus Subcutaneous Insulin Delivery on Glucose Homeostasis in Patients With NIDDM , 1996, Diabetes Care.
[55] A. Giobbie-Hurder,et al. Implantable insulin pump vs multiple-dose insulin for non-insulin-dependent diabetes mellitus: a randomized clinical trial. Department of Veterans Affairs Implantable Insulin Pump Study Group. , 1996, JAMA.
[56] U. Kabadi,et al. Efficacy of insulin and sulfonylurea combination therapy in type II diabetes. A meta-analysis of the randomized placebo-controlled trials. , 1996, Archives of internal medicine.
[57] L. Rossetti. Glucose toxicity: the implications of hyperglycemia in the pathophysiology of diabetes mellitus. , 1995, Clinical and investigative medicine. Medecine clinique et experimentale.
[58] G. Slama,et al. Multicentre Trial of a Programmable Implantable Insulin Pump in Type I Diabetes , 1995, The International journal of artificial organs.
[59] R. DeFronzo,et al. Bedtime Insulin/Daytime Glipizide: Effective Therapy for Sulfonylurea Failures in NIDDM , 1995, Diabetes.
[60] S. Ross,et al. The Efficacy of Acarbose in the Treatment of Patients with NonInsulin-Dependent Diabetes Mellitus: A Multicenter, Controlled Clinical Trial , 1994, Annals of Internal Medicine.
[61] P. Reichard,et al. Mortality and Treatment Side-Effects During Long-Term Intensified Conventional Insulin Treatment in the Stockholm Diabetes Intervention Study , 1994, Diabetes.
[62] J. A. Hunt,et al. The efficacy of acarbose in the treatment of patients with non-insulin-dependent diabetes mellitus , 1994 .
[63] V. Koivisto. Insulin Therapy in Type II Diabetes , 1993, Diabetes Care.
[64] Pi-Sunyer Fx. Short-Term Medical Benefits and Adverse Effects of Weight Loss , 1993 .
[65] S. Genuth,et al. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. , 1993, The New England journal of medicine.
[66] L. Groop,et al. Antibodies to Glutamic Acid Decarboxylase Reveal Latent Autoimmune Diabetes Mellitus in Adults With a Non—Insulin-Dependent Onset of Disease , 1993, Diabetes.
[67] R. Henry,et al. Intensive Conventional Insulin Therapy for Type II Diabetes: Metabolic effects during a 6-mo outpatient trial , 1993, Diabetes Care.
[68] F. Pi‐Sunyer,et al. Medical Hazards of Obesity , 1993, Annals of Internal Medicine.
[69] K. T. Chen,et al. Epidemiology of Diabetes Mellitus , 1992 .
[70] L. Niskanen,et al. Comparison of insulin regimens in patients with non-insulin-dependent diabetes mellitus. , 1992, The New England journal of medicine.
[71] P. Raskin. Combination therapy in NIDDM. , 1992, The New England journal of medicine.
[72] D. Owens,et al. Relationship Between Absorption of Radiolabeled Soluble Insulin, Subcutaneous Blood Flow, and Anthropometry , 1992, Diabetes Care.
[73] R. DeFronzo. Insulin Resistance, Hyperinsulinemia, and Coronary Artery Disease: A Complex Metabolic Web , 1992, Journal of cardiovascular pharmacology.
[74] G. Schernthaner,et al. The effect of insulin treatment on HbA1c, body weight and lipids in type 2 diabetic patients with secondary-failure to sulfonylureas. A five year follow-up study. , 1992, Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme.
[75] J. Pugh,et al. Is Combination Sulfonylurea and Insulin Therapy Useful in NIDDM Patients?: A metaanalysis , 1992, Diabetes Care.
[76] L. Groop,et al. Morning or Bedtime NPH Insulin Combined With Sulfonylurea in Treatment of NIDDM , 1992, Diabetes Care.
[77] A. Greco,et al. The Beta Cell Function in NIDDM Patients with Secondary Failure: , 1992, Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme.
[78] W. Duckworth,et al. Why Intraperitoneal Delivery of Insulin With Implantable Pumps in NIDDM? , 1992, Diabetes.
[79] W. Duckworth,et al. The Department of Veterans Affairs Implanted Insulin Pump Study , 1992, Diabetes Care.
[80] M. Riddle,et al. Combined therapy for obese type 2 diabetes: suppertime mixed insulin with daytime sulfonylurea. , 1992, The American journal of the medical sciences.
[81] R. DeFronzo,et al. Pathogenesis of NIDDM: A Balanced Overview , 1992, Diabetes Care.
[82] S. Heshka,et al. Combination Therapy for NIDDM With Biosynthetic Human Insulin and Glyburide , 1992, Diabetes Care.
[83] S. Efendić,et al. Effects of Combination Therapy With Glyburide and Insulin on Serum Lipid Levels in NIDDM Patients With Secondary Sulfonylurea Failure , 1991, Diabetes Care.
[84] J. Caro. Clinical review 26: Insulin resistance in obese and nonobese man. , 1991, The Journal of clinical endocrinology and metabolism.
[85] J. Talbot,et al. Randomized Trial Comparing Continuous Subcutaneous Insulin Infusion and Conventional Insulin Therapy in Type II Diabetic Patients Poorly Controlled With Sulfonylureas , 1991, Diabetes Care.
[86] R. Vigneri,et al. Treatment of NIDDM patients with secondary failure to glyburide: comparison of the addition of either metformin or bed-time NPH insulin to glyburide. , 1991, Diabete & metabolisme.
[87] J. Galloway. Treatment of NIDDM With Insulin Agonists or Substitutes , 1990, Diabetes Care.
[88] S. Genuth. Insulin Use in NIDDM , 1990, Diabetes Care.
[89] R. Holman,et al. Insulin Use in NIDDM: Rationale Based on Pathophysiology of Disease , 1990, Diabetes Care.
[90] M. Riddle. Evening Insulin Strategy , 1990, Diabetes Care.
[91] T. Bailey,et al. Combination Therapy With Insulin and Sulfonylureas for Type II Diabetes , 1990, Diabetes Care.
[92] H. Lebovitz,et al. Combination Insulin-Sulfonylurea Therapy , 1990, Diabetes Care.
[93] M. Funnell,et al. Feasibility of Adjustment of Insulin Dose by Insulin-Requiring Type II Diabetic Patients , 1990, Diabetes Care.
[94] M. Taskinen,et al. Bedtime Insulin for Suppression of Overnight Free–Fatty Acid, Blood Glucose, and Glucose Production in NIDDM , 1989, Diabetes.
[95] M. Davidson. Futility of Self-Monitoring of Blood Glucose Without Algorithms for Adjusting Insulin Doses , 1986, Diabetes Care.
[96] G. Bray,et al. Management of Obesity by Severe Caloric Restriction , 1985 .
[97] R. Hamman,et al. The Effect of Insulin Treatment on Insulin Secretion and Insulin Action in Type II Diabetes Mellitus , 1985, Diabetes.
[98] W. J. Andrews,et al. Insulin Therapy in Obese, Non-insulin-dependent Diabetes Induces Improvements in Insulin Action and Secretion that Are Maintained for Two Weeks After Insulin Withdrawal , 1984, Diabetes.
[99] K. Polonsky,et al. C-Peptide as a Measure of the Secretion and Hepatic Extraction of Insulin: Pitfalls and Limitations , 1984, Diabetes.
[100] J. A. Scarlett,et al. Insulin Treatment Reverses the Insulin Resistance of Type II Diabetes Mellitus , 1982, Diabetes Care.
[101] L. Mandarino,et al. Dose-response characteristics for effects of insulin on production and utilization of glucose in man. , 1981, The American journal of physiology.
[102] D L McGee,et al. Diabetes and Cardiovascular Risk Factors: The Framingham Study , 1979, Circulation.
[103] R. DeFronzo,et al. Insulin binding to monocytes and insulin action in human obesity, starvation, and refeeding. , 1978, The Journal of clinical investigation.
[104] E. Joslin,et al. Joslin's Diabetes Mellitus , 1971 .
[105] R. Cecil. Textbook of Medicine , 1927 .